THE WHAT? The Estée Lauder Companies has made a minority investment in luxury clinical skincare brand 111SKIN.
THE DETAILS Founded in 2012 by plastic surgeon Dr. Yannis Alexandrides, 111SKIN is built on clinical expertise and its proprietary NAC Y2™ technology, designed to support skin repair and resilience. The brand offers more than 30 products, spanning premium price points from US$50 to US$1,000, and is distributed through luxury retail, e-commerce and high-end spa channels, including Harrods, Nordstrom and Mandarin Oriental. North America accounts for approximately 40% of sales, with additional presence across Europe, the UK, China and APAC. The brand also maintains a strong direct-to-consumer business, representing around 20% of total sales. Dr. Alexandrides will remain actively involved alongside the existing leadership team.
THE WHY? The investment reflects Estée Lauder’s strategy to expand in science-led, high-performance skincare, as consumer demand shifts toward clinically inspired, treatment-driven products linked to longevity and aesthetic procedures.
Source: Estée Lauder Companies
